IQVIA Holdings Inc. $IQV Shares Bought by Northwestern Mutual Wealth Management Co.

Key Points

• Northwestern Mutual Wealth Management increased its IQVIA stake by 3.0% in the second quarter, bringing its holdings to 356,505 shares valued at approximately $68.9 million. Institutional investors collectively own 89.62% of IQVIA.
• IQVIA exceeded quarterly expectations with adjusted EPS of $3.15 versus the $3.03 consensus and revenue of $4.37 billion, up 8.7% year over year. The company issued fiscal 2026 EPS guidance of $12.80–$13.00.
• The board authorized a $2 billion share-repurchase program, covering up to 6.8% of outstanding shares. Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and an average price target of $241.88.

Northwestern Mutual Wealth Management Co. raised its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 3.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 356,505 shares of the medical research company's stock after purchasing an additional 10,317 shares during the period. Northwestern Mutual Wealth Management Co. owned 0.22% of IQVIA worth $68,884,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the company. BlackRock Inc. purchased a new stake in IQVIA during the 2nd quarter worth about $2,811,292,000. Geode Capital Management LLC raised its position in shares of IQVIA by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company's stock worth $982,272,000 after acquiring an additional 24,453 shares in the last quarter. Boston Partners lifted its stake in IQVIA by 14.9% during the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company's stock worth $923,276,000 after purchasing an additional 530,672 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in IQVIA by 16.2% in the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company's stock valued at $856,468,000 after purchasing an additional 528,753 shares in the last quarter. Finally, Invesco Ltd. increased its stake in IQVIA by 15.3% in the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company's stock valued at $526,891,000 after purchasing an additional 367,204 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Performance

Shares of IQV opened at $258.39 on Wednesday. The stock has a market capitalization of $42.53 billion, a P/E ratio of 32.06, a P/E/G ratio of 2.23 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $265.25. The company's fifty day moving average is $225.75 and its two-hundred day moving average is $190.73.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion during the quarter, compared to analysts' expectations of $4.30 billion. During the same period in the prior year, the company posted $2.81 earnings per share. The firm's revenue for the quarter was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its Board of Directors has authorized a share buyback program on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback programs are often an indication that the company's board of directors believes its stock is undervalued.

Insider Activity at IQVIA

In other news, insider W Richard Staub sold 5,500 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the transaction, the insider owned 13,312 shares in the company, valued at $3,097,436.16. This trade represents a 29.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the business's stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the sale, the insider directly owned 2,989 shares in the company, valued at approximately $732,932.69. This represents a 15.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 12,913 shares of company stock valued at $3,098,793 over the last 90 days. Company insiders own 1.70% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on IQV shares. Barclays restated an "overweight" rating on shares of IQVIA in a report on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on shares of IQVIA in a research note on Thursday, July 9th. Royal Bank Of Canada raised their price objective on IQVIA from $221.00 to $247.00 and gave the stock an "outperform" rating in a report on Wednesday, July 29th. Weiss Ratings raised IQVIA from a "hold (c-)" rating to a "hold (c)" rating in a report on Wednesday, July 15th. Finally, JPMorgan Chase & Co. raised their price target on IQVIA from $225.00 to $285.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $241.88.

IQVIA Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source